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We can expect that a better understanding of the patho-
genesis of systemic lupus erythematosus (SLE) will even-
tually lead to improved treatments for this devastating
disorder (’translational medicine’). And if lupus is not a
single disease entity, then different treatment regimens
might be appropriate in different patients (’personalized
medicine’).
As one approach to improving our understanding of
why some people develop lupus, we are interested in the
identification and analysis of monogenic (i.e. Mendelian)
forms of SLE - thinking that they will not only provide
clues to disease causation in specific cases, but that they
will also help to define general molecular concepts of
immune tolerance/dysfunction in humans, and thus
inform the experimental approaches of other researchers
(by highlighting potentially important disease pathways
e.g. the ‘type I interferonopathies’).
Drawing on a well-proven strategy taken in other
‘complex diseases’ (e.g. certain types of cancer, motor
neuron disease, Parkinson disease, Alzheimer disease
etc.), we hypothesise that populations of children
affected by lupus will likely be enriched for Mendelian
forms. We are therefore harnessing the power of next-
generation sequencing technology to identify highly
penetrant genetic susceptibility loci for juvenile SLE. In
this talk, I will discuss our strategy, outline the challenges
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